Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury

Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Neuren Pharmaceuticals chief executive Jon Pilcher says the Kiwi firm is in a privileged position. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
Neuren Pharmaceuticals' boss Jon Pilcher says he was punching the air after leaving a recent successful meeting with the US Food and Drug Administration.Neuren, a local company which develops treatments for neurological disorders including Rett syndrome, has been cleared to begin phase-three trials for the drug NNZ-2591 to treat Phelan-McDermid syndrome. It will be the first-ever phase-three trial in children with the rare genetic condition.The disorders Neuren targets for treatment with its drugs are often debilitating and can ha...

More Markets

Monthly CPI tech takes Stats NZ into the future
Economy

Monthly CPI tech takes Stats NZ into the future

Budget funding for new inflation-reporting tech is a giant leap forward, agency says.

Fonterra leads NZ sharemarket rise
Markets Market Close

Fonterra leads NZ sharemarket rise

The NZX 50 grew by 0.15% to 12,480.05 as Fonterra performed well.

Tom Raynel 26 Jun 2025
NZ sharemarket flat despite export growth
Markets Market close

NZ sharemarket flat despite export growth

The NZ sharemarket dipped as Fletcher Building shares fell further.

Tom Raynel 25 Jun 2025
FMA to focus on private market offers
Markets

FMA to focus on private market offers

The FMA is worried about unsophisticated investors taking the bait.

Pattrick Smellie 25 Jun 2025